Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Institute of Immunology
Street 1: Ya.Gulomov str.74
Street 2:
City: Tashkent
Province:
Post Code: 100060
Country: Uzbekistan
Phone: (99871) 233 08 55
Organization Email: humangenomics.immunology-uzas@yandex.ru
Web Site: http://www.immunology.uz
Other Online Presence:

Focal Point Contact Information

Salutation: Dr.
First Name: Aripova
Last Name: Tamara
Title: Professor
Email: immunology-uzas.aripova@yandex.ru
Phone:  

Alternate Focal Point Contact Information

Salutation: Dr.
First Name: Svetlana
Last Name: Polyarush
Title:  
Email: spolyarusch@yahoo.de
Phone:  

General Information

Board Constituency: Technical agencies
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Academic / Research Institution
Organization Type - Secondary: None
Organization Description:
Institute of Immunology Uzbekistan Academy of Science is one of leading research institutes in Central Asia investigating the genetics peculiarity of human pathogens. For many years several laboratories working on HIV and HCV topics. To the present time the Institute runs the national research project on Ā«Molecular mechanisms of the drug resistance by tuberculosis and HIVĀ» (2011-2015) financed by Uzbekistan government. The one of main goal of this investigation is revelation of full-panel local mutations associated with MDR/XDR. Institute of Immunology is very interesting on an international collaboration and participation in TB-Stop Partnership program
 
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Research and Development

Other Organization Information

Total number of staff in your organization: 51 - 99
Number of full-time staff who are directly involved with TB: 6 - 10
Number of part-time staff who are directly involved with TB: 11 - 25
Number of volunteers who are directly involved with TB: 1 - 5
 
How did you hear about the Stop TB Partnership: Other partners
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Network with other partners
 
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
To develop diagnostic approaches covering/detecting all local significant mutations in the Mycobacterium genome for the early MDR/XDR definition in Uzbek patients with TB.
 

Geographical Reach

Which country is your headquarters located in: Uzbekistan
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Germany
Kyrgyzstan
Russian Federation

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

Drug-Resistant TB:
We plan to obtain a full panel of local MDR mutations

TB-HIV:
We will define the specific prevalent mutations in the Uzbek patients co-infected by TB and HIV and the prognostic meaning of such mutations.

Laboratory Strengthening:
The developed local MDR/XDR mutations panel will be used to develop modern methods based on the new-Nucleic Acid Amplification (NAA) technologies.

New Diagnostics:
The developed local MDR/XDR mutations panel will be used to develop modern methods based on the new-Nucleic Acid Amplification (NAA) technologies.

New TB Drugs:
By using a recombinant protein technology it will be obtained the model systems for the screening of candidate compounds that have a strong inhibition activity against Mycobacterium`s key enzymes, low toxicity for human organism and relative chip in the price of drug.

Fundamental Research:
Additionally we would like to understand the general molecular mechanism leading to the drug resistance. Especially an influence of DNA- adduct and other co-factors during treatment.

Declaration

Declaration of interests:
No conflicts of interest were delacred.

Application date: February 8, 2013
Last updated: February 8, 2013